false Q1 0001029142 --12-31 false false P5Y P4Y P3Y P4Y3M4D P4Y2M5D P3Y0M18D 0.0003 P4Y6M0D P4Y6M0D P2Y10M25D 0.0192 0001029142 2021-01-01 2021-03-31 xbrli:shares 0001029142 2021-05-03 iso4217:USD 0001029142 2021-03-31 0001029142 2020-12-31 0001029142 dvax:SeriesBConvertiblePreferredStockMember 2021-03-31 0001029142 dvax:SeriesBConvertiblePreferredStockMember 2020-12-31 iso4217:USD xbrli:shares 0001029142 us-gaap:ProductMember 2021-01-01 2021-03-31 0001029142 us-gaap:ProductMember 2020-01-01 2020-03-31 0001029142 dvax:OtherRevenueMember 2021-01-01 2021-03-31 0001029142 dvax:OtherRevenueMember 2020-01-01 2020-03-31 0001029142 2020-01-01 2020-03-31 0001029142 us-gaap:CommonStockMember 2020-12-31 0001029142 us-gaap:PreferredStockMember 2020-12-31 0001029142 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001029142 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001029142 us-gaap:RetainedEarningsMember 2020-12-31 0001029142 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001029142 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001029142 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001029142 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001029142 us-gaap:CommonStockMember 2021-03-31 0001029142 us-gaap:PreferredStockMember 2021-03-31 0001029142 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001029142 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001029142 us-gaap:RetainedEarningsMember 2021-03-31 0001029142 us-gaap:CommonStockMember 2019-12-31 0001029142 us-gaap:PreferredStockMember 2019-12-31 0001029142 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001029142 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001029142 us-gaap:RetainedEarningsMember 2019-12-31 0001029142 2019-12-31 0001029142 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001029142 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001029142 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001029142 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001029142 us-gaap:CommonStockMember 2020-03-31 0001029142 us-gaap:PreferredStockMember 2020-03-31 0001029142 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001029142 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001029142 us-gaap:RetainedEarningsMember 2020-03-31 0001029142 2020-03-31 0001029142 dvax:HEPLISAVBMember 2021-01-01 2021-03-31 dvax:Segment 0001029142 srt:MaximumMember 2021-01-01 2021-03-31 0001029142 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001029142 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001029142 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001029142 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001029142 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001029142 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001029142 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001029142 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001029142 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001029142 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001029142 us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001029142 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001029142 us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001029142 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001029142 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001029142 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001029142 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001029142 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001029142 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001029142 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001029142 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001029142 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001029142 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001029142 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001029142 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001029142 us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001029142 us-gaap:FairValueInputsLevel3Member 2021-03-31 xbrli:pure 0001029142 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001029142 us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-03-31 0001029142 us-gaap:CashAndCashEquivalentsMember us-gaap:CashMember 2021-03-31 0001029142 us-gaap:CashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember 2021-03-31 0001029142 us-gaap:CashAndCashEquivalentsMember 2021-03-31 0001029142 us-gaap:AvailableforsaleSecuritiesMember us-gaap:USTreasurySecuritiesMember 2021-03-31 0001029142 us-gaap:AvailableforsaleSecuritiesMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-03-31 0001029142 us-gaap:AvailableforsaleSecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2021-03-31 0001029142 us-gaap:AvailableforsaleSecuritiesMember 2021-03-31 0001029142 us-gaap:CashAndCashEquivalentsMember us-gaap:CashMember 2020-12-31 0001029142 us-gaap:CashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember 2020-12-31 0001029142 us-gaap:CashAndCashEquivalentsMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001029142 us-gaap:CashAndCashEquivalentsMember 2020-12-31 0001029142 us-gaap:AvailableforsaleSecuritiesMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0001029142 us-gaap:AvailableforsaleSecuritiesMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001029142 us-gaap:AvailableforsaleSecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001029142 us-gaap:AvailableforsaleSecuritiesMember 2020-12-31 utr:sqft 0001029142 stpr:CA dvax:PowellStreetSubleaseMember 2019-07-31 0001029142 stpr:CA dvax:PowellStreetSubleaseMember 2019-07-01 2019-07-31 0001029142 stpr:CA dvax:PowellStreetSubleaseMember 2021-01-01 2021-03-31 0001029142 stpr:CA dvax:HortonStreetMasterLeaseMember 2018-09-17 0001029142 stpr:CA dvax:HortonStreetMasterLeaseMember 2018-09-16 2018-09-17 0001029142 dvax:HortonStreetSubleaseMember stpr:CA 2019-07-31 0001029142 dvax:HortonStreetSubleaseMember stpr:CA 2019-07-01 2019-07-31 0001029142 dvax:HortonStreetSubleaseMember us-gaap:OtherNonoperatingIncomeExpenseMember stpr:CA 2021-01-01 2021-03-31 0001029142 dvax:HortonStreetSubleaseMember us-gaap:OtherNonoperatingIncomeExpenseMember stpr:CA 2020-01-01 2020-03-31 0001029142 dvax:HortonStreetMasterLeaseMember 2021-03-31 0001029142 dvax:CRGServicingLLCMember 2018-02-20 0001029142 dvax:CRGServicingLLCMember 2019-03-29 0001029142 dvax:CRGServicingLLCMember 2021-03-31 0001029142 dvax:CRGServicingLLCMember 2021-01-01 2021-03-31 0001029142 dvax:CRGServicingLLCMember 2020-01-01 2020-09-30 iso4217:EUR 0001029142 2004-12-31 0001029142 dvax:SymphonyDynamoHoldingsLlcMember 2009-11-30 0001029142 dvax:SymphonyDynamoHoldingsLlcMember 2009-11-01 2009-11-30 0001029142 dvax:SymphonyDynamoHoldingsLlcMember 2020-08-01 2020-08-31 0001029142 dvax:SymphonyDynamoHoldingsLlcMember dvax:AssetPurchaseAgreementMember 2021-03-31 0001029142 dvax:CoalitionForEpidemicPreparednessInnovationsMember 2021-01-31 0001029142 dvax:CoalitionForEpidemicPreparednessInnovationsMember 2021-02-28 0001029142 dvax:CoalitionForEpidemicPreparednessInnovationsMember 2021-03-31 0001029142 dvax:SupplyAgreementMember dvax:ValnevaSEMember 2020-12-31 0001029142 dvax:SupplyAgreementMember dvax:ValnevaSEMember 2020-10-01 2020-12-31 0001029142 dvax:ValnevaSEMember 2021-03-31 0001029142 dvax:CRGServicingLLCMember 2018-02-19 2018-02-20 0001029142 dvax:CRGServicingLLCMember 2020-09-30 0001029142 dvax:LoanAgreementMember 2019-07-31 0001029142 dvax:LoanAgreementMember 2019-08-01 0001029142 dvax:LoanAgreementMember 2018-02-19 2018-02-20 0001029142 dvax:LoanAgreementMember 2018-02-20 0001029142 dvax:LoanAgreementMember 2021-01-01 2021-03-31 0001029142 dvax:LoanAgreementMember 2020-01-01 2020-03-31 0001029142 dvax:CpG1018Member 2021-01-01 2021-03-31 0001029142 dvax:HEPLISAVBMember 2020-01-01 2020-03-31 0001029142 us-gaap:RevenueFromContractWithCustomerMember dvax:HEPLISAVBMember us-gaap:CreditConcentrationRiskMember 2021-01-01 2021-03-31 0001029142 us-gaap:RevenueFromContractWithCustomerMember dvax:CpG1018Member us-gaap:CreditConcentrationRiskMember 2021-01-01 2021-03-31 0001029142 dvax:HEPLISAVBMember us-gaap:AllowanceForNotesReceivableMember 2020-12-31 0001029142 dvax:HEPLISAVBMember us-gaap:AllowanceForNotesReceivableMember 2021-01-01 2021-03-31 0001029142 dvax:HEPLISAVBMember us-gaap:AllowanceForNotesReceivableMember 2021-03-31 0001029142 dvax:HEPLISAVBMember 2020-12-31 0001029142 dvax:HEPLISAVBMember 2021-03-31 0001029142 dvax:StockOptionsAndShareAwardsMember 2021-01-01 2021-03-31 0001029142 dvax:StockOptionsAndShareAwardsMember 2020-01-01 2020-03-31 0001029142 us-gaap:ConvertiblePreferredStockMember 2021-01-01 2021-03-31 0001029142 us-gaap:ConvertiblePreferredStockMember 2020-01-01 2020-03-31 0001029142 us-gaap:WarrantMember 2021-01-01 2021-03-31 0001029142 2019-08-01 2019-08-31 0001029142 2019-08-31 0001029142 dvax:SeriesBConvertiblePreferredStockMember 2019-08-01 2019-08-31 0001029142 dvax:SeriesBConvertiblePreferredStockMember 2019-08-31 0001029142 srt:MaximumMember us-gaap:IPOMember 2019-08-31 0001029142 us-gaap:IPOMember 2019-08-31 0001029142 dvax:SeriesBConvertiblePreferredStockMember us-gaap:IPOMember 2019-08-31 0001029142 us-gaap:IPOMember 2019-08-01 2019-08-31 0001029142 dvax:BainLifeSciencesMember 2019-08-01 2019-08-31 0001029142 dvax:BainCapitalLifeSciencesFundLimitedPartnerMember 2019-08-01 2019-08-31 0001029142 dvax:BainCapitalLifeSciencesFundLimitedPartnerMember dvax:SeriesBConvertiblePreferredStockMember 2019-08-01 2019-08-31 0001029142 dvax:BainCapitalLifeSciencesFundLimitedPartnerMember 2019-08-31 0001029142 dvax:BCIPLifeSciencesAssociatesLimitedPartnersMember 2019-08-01 2019-08-31 0001029142 dvax:BCIPLifeSciencesAssociatesLimitedPartnersMember dvax:SeriesBConvertiblePreferredStockMember 2019-08-01 2019-08-31 0001029142 dvax:BCIPLifeSciencesAssociatesLimitedPartnersMember 2019-08-31 0001029142 us-gaap:CommonStockMember 2020-03-11 0001029142 us-gaap:IPOMember 2020-05-31 0001029142 us-gaap:IPOMember srt:MaximumMember 2020-05-01 2020-05-31 0001029142 us-gaap:IPOMember dvax:BainCapitalLifeSciencesFundLimitedPartnerMember 2020-05-01 2020-05-31 0001029142 us-gaap:IPOMember 2020-05-01 2020-05-31 0001029142 srt:MaximumMember dvax:TwentySeventeenAtTheMarketAgreementMember 2017-11-03 2017-11-03 0001029142 srt:MaximumMember dvax:TwentySeventeenAtTheMarketAgreementMember 2017-11-03 0001029142 dvax:TwentySeventeenAtTheMarketAgreementMember 2021-01-01 2021-03-31 0001029142 srt:MaximumMember 2020-08-06 2020-08-06 0001029142 us-gaap:CommonStockMember dvax:SeriesBConvertiblePreferredStockMember 2021-03-31 0001029142 srt:MinimumMember dvax:SeriesBConvertiblePreferredStockMember 2021-01-01 2021-03-31 0001029142 srt:MaximumMember dvax:SeriesBConvertiblePreferredStockMember 2021-01-01 2021-03-31 0001029142 dvax:SeriesBConvertiblePreferredStockMember 2021-01-01 2021-03-31 0001029142 us-gaap:WarrantMember 2021-03-31 0001029142 us-gaap:WarrantMember srt:MinimumMember 2021-01-01 2021-03-31 0001029142 us-gaap:WarrantMember srt:MaximumMember 2021-01-01 2021-03-31 0001029142 us-gaap:WarrantMember 2019-08-12 0001029142 us-gaap:OtherNonoperatingIncomeExpenseMember us-gaap:WarrantMember 2021-01-01 2021-03-31 0001029142 dvax:TwoThousandAndEighteenEquityIncentivePlanMember 2021-01-31 0001029142 dvax:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2021-03-31 0001029142 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001029142 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2021-01-01 2021-03-31 0001029142 dvax:UnvestedMember 2021-01-01 2021-03-31 0001029142 dvax:VestedMember 2021-01-01 2021-03-31 0001029142 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001029142 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001029142 us-gaap:RestrictedStockUnitsRSUMember 2021-03-31 0001029142 dvax:PerformanceBasedRestrictedStockUnitsMember 2021-01-01 2021-03-31 0001029142 dvax:PerformanceBasedRestrictedStockUnitsMember 2021-03-31 0001029142 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001029142 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001029142 dvax:MarketBasedPerformanceStockUnitMember 2021-01-01 2021-03-31 0001029142 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2020-01-01 2020-03-31 0001029142 dvax:MarketBasedPerformanceStockUnitMember srt:MinimumMember 2021-01-01 2021-03-31 0001029142 dvax:MarketBasedPerformanceStockUnitMember srt:MaximumMember 2021-01-01 2021-03-31 0001029142 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001029142 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001029142 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-03-31 0001029142 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-03-31 0001029142 us-gaap:CostOfSalesMember 2021-01-01 2021-03-31 0001029142 us-gaap:CostOfSalesMember 2020-01-01 2020-03-31 0001029142 us-gaap:InventoriesMember 2021-01-01 2021-03-31 0001029142 us-gaap:InventoriesMember 2020-01-01 2020-03-31 0001029142 dvax:CoalitionForEpidemicPreparednessInnovationsMember dvax:ReservationAgreementMember 2021-03-31 0001029142 dvax:CoalitionForEpidemicPreparednessInnovationsMember dvax:ReservationAgreementMember us-gaap:SubsequentEventMember 2021-05-02 2021-05-03 0001029142 dvax:CoalitionForEpidemicPreparednessInnovationsMember dvax:ReservationAgreementMember us-gaap:SubsequentEventMember 2021-05-03

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021   

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from           to           .

Commission file number: 001-34207

 

Dynavax Technologies Corporation

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

33-0728374

(State or other jurisdiction of
incorporation or organization)

 

(IRS Employer
Identification No.)

2100 Powell Street, Suite 900

Emeryville, CA 94608

(510) 848-5100

(Address, including Zip Code, and telephone number, including area code, of the registrant’s principal executive offices)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:

Trading symbol(s):

Name of each exchange on which registered:

Common Stock, $0.001 par value

DVAX

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registration was required to submit such files). Yes  No 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

 

Accelerated filer

 

 

 

 

 

Non-accelerated filer

 

 

Smaller reporting company

 

 

 

 

 

 

 

 

Emerging growth company

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes  No 

As of May 3, 2021, the registrant had outstanding 114,588,212 shares of common stock.

 

 

 


 

INDEX

DYNAVAX TECHNOLOGIES CORPORATION

 

 

Page No.

PART I FINANCIAL INFORMATION

 

 

Item 1.

Financial Statements (unaudited)

6

 

Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020

6

 

Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2021 and 2020

7

 

Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2021 and 2020

7

 

Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2021 and 2020

8

 

Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2021 and 2020

9

 

Notes to Condensed Consolidated Financial Statements

10

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

26

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

33

Item 4.

Controls and Procedures

33

 

PART II OTHER INFORMATION

 

 

Item 1.

Legal Proceedings

34

Item 1A.

Risk Factors

34

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

54

Item 5.

Other Information

54

Item 6.

Exhibits

55

 

SIGNATURES

57

 

2


 

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to a number of risks and uncertainties. All statements that are not historical facts are forward-looking statements, including statements about the direct and indirect impact of the ongoing COVID-19 global pandemic on our business and operations, including sales of HEPLISAV-B®, our ability to successfully commercialize HEPLISAV-B, our anticipated market opportunity and level of sales of HEPLISAV-B, our ability to manufacture sufficient supply of HEPLISAV-B to meet future demand, our business, collaboration and regulatory strategy, our ability to successfully support the development and commercialization of other vaccines containing our CpG 1018™ adjuvant, including any potential vaccine for COVID-19, our ability to manufacture sufficient supply of CpG 1018 to meet potential future demand in connection with new vaccines, including any potential COVID-19 vaccine, and to meet regulatory requirements, uncertainty regarding our capital needs and future operating results and profitability, anticipated sources of funds, liquidity and cash needs, as well as our plans, objectives, strategies, expectations and intentions. These statements appear throughout this Quarterly Report on Form 10-Q and can be identified by the use of forward-looking language such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “future,” or “intend,” or the negative of these terms or other variations or comparable terminology.

Actual results may vary materially from those in our forward-looking statements as a result of various factors that are identified in “Item 1A—Risk Factors” and “Item 2—Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this document. No assurance can be given that the risk factors described in this Quarterly Report on Form 10-Q are all of the factors that could cause actual results to vary materially from the forward-looking statements. All forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Readers should not place undue reliance on these forward-looking statements and are cautioned that any such forward-looking statements are not guarantees of future performance. We assume no obligation to update any forward-looking statements.

This Quarterly Report on Form 10-Q includes trademarks and registered trademarks of Dynavax Technologies Corporation. Products or service names of other companies mentioned in this Quarterly Report on Form 10-Q may be trademarks or registered trademarks of their respective owners. References herein to “we,” “our,” “us,” “Dynavax” or the “Company” refer to Dynavax Technologies Corporation and its subsidiaries.

 


3


 

RISK FACTOR SUMMARY

Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks and uncertainties that we face. Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks and uncertainties that we face, can be found in the more detailed discussion that follows this summary, and the below summary is qualified in its entirety by that more complete discussion of such risks and uncertainties. You should consider carefully the risks and uncertainties described herein as part of your evaluation of an investment in our securities:

 

HEPLISAV-B has been launched in the United States, and approved in the European Union, and there is significant competition in the marketplace. Since this is our first marketed product, the timing of uptake and distribution efforts are unpredictable and there is a risk that we may not achieve and sustain commercial success for HEPLISAV-B.

 

Our business and operations have been and may continue to be adversely affected by the evolving and ongoing COVID-19 global pandemic. While we have entered into collaborative relationships to develop vaccines utilizing CpG 1018, including collaborations to develop a vaccine for COVID-19, our collaborators generally have primary responsibility for the development, conduct of clinical trials, and for seeking and obtaining regulatory approval, and these collaborations may not be successful. If the combination of patents, trade secrets and other proprietary rights that we rely on to protect our intellectual property rights in CpG 1018 are inadequate; we may be unable to realize any commercial benefit from the development of a vaccine containing CpG 1018.

 

Our financial results may vary significantly from quarter to quarter or may fall below the expectations of investors or securities analysts, each of which may adversely affect our stock price.

 

We face uncertainty regarding coverage, pricing and reimbursement and the practices of third-party payors, which may make it difficult or impossible to sell our product or product candidates on commercially reasonable terms.

 

We are subject to ongoing United States Food and Drug Administration (“FDA”) and European Medicines Agency (“EMA”) post-marketing obligations concerning HEPLISAV-B, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with HEPLISAV-B.

 

If HEPLISAV-B or any products we develop are not accepted by the market or if regulatory agencies limit our labeling indications, require labeling content that diminishes market uptake of HEPLISAV-B or any other products we develop, or limit our marketing claims, we may be unable to generate significant revenues, if any.

 

Many of our competitors have greater financial resources and expertise than we do. If we are unable to successfully compete with existing or potential competitors as a result of these disadvantages, we may be unable to generate sufficient or any revenues and our business will be harmed.

 

We have incurred net losses in each year since our inception and anticipate that we will continue to incur significant losses for the foreseeable future unless we can successfully commercialize HEPLISAV-B or continue to sell significant quantities of CpG 1018, and if we are unable to achieve and sustain profitability, the market value of our common stock will likely decline. Until we are able to generate significant revenues or achieve profitability through product sales, we will require substantial additional capital to finance our operations.

 

We may develop, seek regulatory approval for and market HEPLISAV-B or any other product candidates we may develop outside the U.S., requiring a significant commitment of resources. Failure to successfully manage our international operations could result in significant unanticipated costs and delays in regulatory approval or commercialization of our product candidates.

 

Clinical trials for our commercial product and product candidates are expensive and time consuming, may take longer than we expect or may not be completed at all, and their outcomes are uncertain.

 

As a biopharmaceutical company, we engage clinical research organizations (“CROs”) to conduct clinical studies, and failure by us or our CROs to conduct a clinical study in accordance with good clinical practice standards and other applicable regulatory requirements could result in disqualification of the applicable clinical trial from consideration in support of approval of a potential product.

 

Regulatory authorities may require more clinical trials for our product candidates than we currently expect or are conducting before granting regulatory approval, if regulatory approval is granted at all. Our clinical trials may be extended which may lead to substantial delays in the regulatory approval process for our product candidates and may impair our ability to generate revenues.

4


 

HEPLISAV-B and most of our earlier stage programs, including our CpG 1018 adjuvant rely on oligonucleotide toll-like receptor (“TLR”) agonists. Serious adverse event data relating to TLR agonists may require us to reduce the scope of or discontinue our operations, or reevaluate the viability of strategic alternatives.

 

As we plan for broader commercialization of HEPLISAV-B and for expanded capacity to manufacture CpG 1018, our financial commitments to increase supply capacity might outpace actual demand for our products. Also, if we are unable to maintain our production operations in Dusseldorf and our existing supplier for CpG 1018, we would have to establish alternate qualified manufacturing capabilities, which could result in significant additional operating costs and delays in developing and commercializing HEPLISAV-B and any potential vaccine utilizing CpG 1018. There can be no assurance that we or other third parties will be able to produce CpG 1018 at a cost, quantity and quality sufficient to support our existing or any future collaborations.

 

We rely on our facility in Düsseldorf, Germany and third parties to supply materials or perform processes necessary to manufacture HEPLISAV-B. We rely on a limited number of suppliers to produce the oligonucleotides we require for development and commercialization. Additionally, we have limited experience in manufacturing our product candidates in commercial quantities. With respect to HEPLISAV-B, we have switched to a pre-filled syringe presentation of the vaccine and our ability to meet future demand will depend on our ability to manufacture sufficient supply in this presentation.

 

As we continue to grow as a commercial organization and enter into supply agreements with customers, those supply agreements will have obligations to deliver product for which we are reliant upon third parties to manufacture on our behalf.

 

HEPLISAV-B is subject to regulatory obligations and continued regulatory review, and if we receive regulatory approval for our other product candidates, we will be subject to ongoing FDA and foreign regulatory obligations and continued regulatory review for such products.

 

A key part of our business strategy for products in development is to establish collaborative relationships to help fund development and commercialization of our product candidates and research programs. We may not succeed in establishing and maintaining collaborative relationships, which may significantly limit our ability to continue to develop and commercialize those products and programs, if at all.

 

The term loan agreement we entered into in February 2018 imposes significant operating and financial restrictions on us that may prevent us from pursuing certain business opportunities and restrict our ability to operate our business.

 

We rely on CROs and clinical sites and investigators for our clinical trials. If these third parties do not fulfill their contractual obligations or meet expected deadlines, our planned clinical trials may be delayed and we may fail to obtain the regulatory approvals necessary to commercialize our product candidates.

 

As we focus on commercialization of HEPLISAV-B, we may encounter difficulties in managing our commercial growth and expanding our operations successfully.

 

If we fail to comply with the extensive requirements applicable to biopharmaceutical manufacturers and marketers under the healthcare fraud and abuse, anticorruption, privacy, transparency and other laws of the jurisdictions in which we conduct our business, we may be subject to significant liability.

 

The loss of key personnel could delay or prevent achieving our objectives. In addition, our continued growth to support commercialization may result in difficulties in managing our growth and expanding our operations successfully.

 

We face product liability exposure, which, if not covered by insurance, could result in significant financial liability. Our business operations are vulnerable to interruptions by natural disasters, health epidemics and other catastrophic events beyond our control, the occurrence of which could materially harm our manufacturing, distribution, sales, business operations and financial results. Significant disruptions of information technology systems or breaches of data security could also adversely affect our business.

 

We rely on licenses to intellectual property from third parties. Impairment of these licenses or our inability to maintain them would severely harm our business.

 

If third parties successfully assert that we have infringed their patents and proprietary rights or challenge our patents and proprietary rights, we may become involved in intellectual property disputes and litigation that would be costly, time consuming and delay or prevent development or commercialization of our product candidates.

 

Future sales of our common stock or the perception that such sales may occur in the public market could cause our stock price to fall.

 

5


 

PART I. FINANCIAL INFORMATION

 

ITEM 1.

FINANCIAL STATEMENTS

Dynavax Technologies Corporation

Condensed Consolidated Balance Sheets

(In thousands, except per share amounts)

 

 

March 31,

 

 

December 31,

 

 

2021

 

 

2020

 

 

(unaudited)

 

 

(Note 1)

 

Assets

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

Cash and cash equivalents

$

79,055

 

 

$

32,073

 

Marketable securities available-for-sale

 

153,619

 

 

 

132,963

 

Accounts and other receivables, net

 

83,994

 

 

 

22,661

 

Inventories, net

 

68,846

 

 

 

63,689

 

Prepaid manufacturing

 

32,642

 

 

 

29,423

 

Prepaid expenses and other current assets

 

9,377

 

 

 

9,206

 

Total current assets

 

427,533

 

 

 

290,015

 

Property and equipment, net

 

30,696

 

 

 

30,567

 

Operating lease right-of-use assets

 

25,799

 

 

 

26,583

 

Goodwill

 

2,197

 

 

 

2,297

 

Restricted cash

 

226

 

 

 

237

 

Other assets

 

3,668

 

 

 

3,573

 

Total assets

$

490,119

 

 

$

353,272

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

Accounts payable

$

3,154

 

 

$

3,312

 

Accrued research and development

 

2,890

 

 

 

2,805

 

Accrued liabilities

 

16,083

 

 

 

19,099

 

Warrant liability

 

31,737

 

 

 

10,736

 

Deferred revenue

 

52,202

 

 

 

38,212

 

Other current liabilities

 

3,356

 

 

 

3,247

 

Total current liabilities

 

109,422

 

 

 

77,411

 

Long-term debt, net of debt discount of $1,016 and $1,094 at March 31, 2021 and

   December 31, 2020, respectively

 

179,889

 

 

 

179,811

 

Long-term deferred revenue

 

64,350

 

 

 

-

 

Long-term portion of lease liabilities

 

33,795

 

 

 

34,789

 

Other long-term liabilities

 

2,901

 

 

 

2,568

 

Total liabilities

 

390,357

 

 

 

294,579

 

Commitments and contingencies (Note 5)

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

Preferred stock: $0.001 par value

 

 

 

 

 

 

 

Authorized: 5,000 shares; Issued and outstanding:

 

-

 

 

 

-

 

Series B Convertible Preferred stock  ̶  4 shares at March 31, 2021

   and December 31, 2020

 

-

 

 

 

-

 

Common stock: $0.001 par value; 278,000 shares authorized at

   March 31, 2021 and December 31, 2020; 114,563 shares and 110,190

   shares issued and outstanding at March 31, 2021 and December 31, 2020,

   respectively

 

114

 

 

 

110

 

Additional paid-in capital

 

1,393,947

 

 

 

1,352,374

 

Accumulated other comprehensive (loss) gain

 

(1,126

)

 

 

273

 

Accumulated deficit

 

(1,293,173

)

 

 

(1,294,064

)

Total stockholders’ equity

 

99,762

 

 

 

58,693

 

Total liabilities and stockholders’ equity

$

490,119

 

 

$

353,272

 

 

See accompanying notes.

6


Dynavax Technologies Corporation

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

(Unaudited)

 

 

 

Three Months Ended March 31

 

 

 

2021

 

 

2020

 

Revenues:

 

 

 

 

 

 

 

 

Product revenue, net

 

$

82,885

 

 

$

10,514

 

Other revenue

 

 

450

 

 

 

405

 

Total revenues

 

 

83,335

 

 

 

10,919

 

Operating expenses:

 

 

 

 

 

 

 

 

Cost of sales - product

 

 

24,625

 

 

 

2,354

 

Cost of sales - amortization of intangible assets

 

 

-

 

 

 

2,298

 

Research and development

 

 

7,758

 

 

 

4,653

 

Selling, general and administrative

 

 

22,423

 

 

 

20,926

 

Total operating expenses

 

 

54,806

 

 

 

30,231

 

Income (loss) from operations

 

 

28,529

 

 

 

(19,312

)

Other income (expense):

 

 

 

 

 

 

 

 

Interest income

 

 

47

 

 

 

590

 

Interest expense

 

 

(4,712

)

 

 

(4,731

)

Sublease income

 

 

2,022

 

 

 

1,926

 

Change in fair value of warrant liability (Note 10)

 

 

(25,552

)

 

 

8,610

 

Other

 

 

557

 

 

 

322

 

Net income (loss)

 

 

891

 

 

 

(12,595

)

Net income (loss) per share attributable to common stockholders

 

 

 

 

 

 

 

 

Basic

 

$

0.01

 

 

$

(0.15

)

Diluted

 

$

0.01

 

 

$

(0.25

)

Weighted-average shares used in computing net income (loss) per share attributable to common stockholders:

 

 

 

 

 

 

 

 

Basic

 

 

112,035

 

 

 

85,477

 

Diluted

 

 

113,469

 

 

 

85,648

 

 

Condensed Consolidated Statements of Comprehensive Loss

(In thousands)

(Unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2021

 

 

2020

 

Net income (loss)

 

$

891

 

 

$

(12,595

)

Other comprehensive income (loss), net of tax:

 

 

 

 

 

 

 

 

Change in unrealized gain on marketable securities available-

   for-sale

 

 

(9

)

 

 

291

 

Foreign currency translation adjustments

 

 

(1,390

)

 

 

(479

)

Total other comprehensive loss

 

 

(1,399

)

 

 

(188

)

Total comprehensive loss

 

$

(508

)

 

$

(12,783

)

 

See accompanying notes.

 

 

7


 

Dynavax Technologies Corporation

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands)

(Unaudited)

 

 

 

Common Stock

 

 

Preferred Stock

 

 

Additional

Paid-In

 

 

Accumulated

Other

Comprehensive

 

 

Accumulated

 

 

Total

Stockholders'

 

Three Months Ended March 31, 2021

 

Shares

 

 

Par Amount

 

 

Shares

 

 

Par Amount

 

 

Capital

 

 

(Loss) Income

 

 

Deficit

 

 

Equity

 

Balances at December 31, 2020

 

 

110,190

 

 

$

110

 

 

 

4

 

 

$

-

 

 

$

1,352,374

 

 

$

273

 

 

$

(1,294,064

)

 

$

58,693

 

Exercise of warrants

 

 

750

 

 

 

1

 

 

 

-

 

 

 

-

 

 

 

7,927

 

 

 

-

 

 

 

-

 

 

 

7,928

 

Issuance of common stock upon exercise of stock options and restricted stock awards, net

 

 

640

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

387

 

 

 

-

 

 

 

-

 

 

 

387

 

Issuance of common stock under Employee Stock Purchase Plan

 

 

104

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

383

 

 

 

-

 

 

 

-

 

 

 

383

 

Issuance of common stock, net of issuance costs, in conjunction with an At Market Sales

   Agreement (see Note 10)

 

 

2,879

 

 

 

3

 

 

 

-

 

 

 

-

 

 

 

28,153

 

 

 

-

 

 

 

-

 

 

 

28,156

 

Stock compensation expense

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

4,723

 

 

 

-

 

 

 

-

 

 

 

4,723

 

Total other comprehensive loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(1,399

)

 

 

-

 

 

 

(1,399

)

Net income

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

891

 

 

 

891

 

Balances at March 31, 2021

 

 

114,563

 

 

$

114

 

 

 

4

 

 

$

-

 

 

$

1,393,947

 

 

$

(1,126

)

 

$

(1,293,173

)

 

$

99,762

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common Stock

 

 

Preferred Stock

 

 

Additional

Paid-In

 

 

Accumulated

Other

Comprehensive

 

 

Accumulated

 

 

Total

Stockholders'

 

Three Months March 31, 2020

 

Shares

 

 

Par Amount

 

 

Shares

 

 

Par Amount

 

 

Capital

 

 

(Loss) Income

 

 

Deficit

 

 

Equity

 

Balances at December 31, 2019

 

 

83,871

 

 

$

84

 

 

 

5

 

 

$

-

 

 

$

1,229,417

 

 

$

(2,387

)

 

$

(1,218,824

)

 

$

8,290

 

Issuance (withholding) of common stock upon exercise of stock options and restricted stock awards, net

 

 

728

 

 

 

1

 

 

 

-

 

 

 

-

 

 

 

(2

)

 

 

-

 

 

 

-

 

 

 

(1

)

Issuance of common stock under Employee Stock Purchase Plan

 

 

91

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

311

 

 

 

-

 

 

 

-

 

 

 

311

 

Issuance of common stock, net of issuance costs, in conjunction with an At Market Sales

   Agreement (see Note 10)

 

 

2,909

 

 

 

3

 

 

 

-

 

 

 

-

 

 

 

14,226

 

 

 

-

 

 

 

-

 

 

 

14,229

 

Stock compensation expense

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,778

 

 

 

-

 

 

 

-

 

 

 

1,778

 

Total other comprehensive loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(188

)

 

 

-

 

 

 

(188

)

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(12,595

)

 

 

(12,595

)

Balances at March 31, 2020

 

 

87,599

 

 

$

88

 

 

 

5

 

 

$

-

 

 

$

1,245,730

 

 

$

(2,575

)

 

$

(1,231,419

)

 

$

11,824

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

See accompanying notes.

 

 

8


 

Dynavax Technologies Corporation

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

 

 

Three Months Ended March 31,

 

 

2021

 

 

2020

 

Operating activities

 

 

 

 

 

 

 

Net income (loss)

$

891

 

 

$

(12,595

)

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

 

 

 

 

 

 

 

Depreciation and amortization

 

1,106

 

 

 

1,014

 

Amortization of right-of-use assets

 

653

 

 

 

634

 

Gain on disposal of property and equipment and from lease termination

 

-

 

 

 

(76

)

Amortization of premium (accretion of discounts) on marketable securities

 

221

 

 

 

(87

)

Change in fair value of warrant liability

 

25,552

 

 

 

(8,610

)

Stock compensation expense

 

4,723

 

 

 

1,778

 

Cost of sales - amortization of intangible assets

 

-

 

 

 

2,298

 

Non-cash interest expense

 

414

 

 

 

1,338

 

Tenant improvements provided by the landlord

 

-

 

 

 

908

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

Accounts and other receivables, net

 

(61,333

)

 

 

751

 

Inventories, net

 

(5,157

)

 

 

(6,767

)

Prepaid manufacturing

 

(3,219

)

 

 

-

 

Prepaid expenses and other current assets

 

(171

)

 

 

(1,000

)

Other assets

 

(95

)

 

 

43

 

Accounts payable

 

(295

)

 

 

(2,095

)

Lease liabilities

 

(751

)

 

 

(672

)

Deferred revenue

 

78,340

 

 

 

-

 

Accrued liabilities and other liabilities

 

(2,847

)

 

 

(3,728

)

Net cash provided by (used in) operating activities

 

38,032

 

 

 

(26,866

)

Investing activities

 

 

 

 

 

 

 

Acquisition of technology licenses

 

-

 

 

 

(7,000

)

Purchases of marketable securities

 

(72,016

)

 

 

(17,985

)

Proceeds from maturities and redemptions of marketable securities

 

51,130

 

 

 

37,900

 

Purchases of property and equipment, net

 

(1,747

)

 

 

(2,352

)

Net cash (used in) provided by investing activities

 

(22,633

)

 

 

10,563

 

Financing activities

 

 

 

 

 

 

 

Proceeds from issuance of common stock, net

 

28,156

 

 

 

14,229

 

Proceeds from exercise of warrants

 

3,377

 

 

 

-

 

Proceeds (tax withholding) from exercise of stock options and restricted stock awards, net

 

387

 

 

 

(1

)

Proceeds from Employee Stock Purchase Plan

 

383

 

 

 

311

 

Net cash provided by financing activities

 

32,303

 

 

 

14,539

 

Effect of exchange rate changes on cash, cash equivalents and restricted cash

 

(731

)

 

 

(225

)

Net increase (decrease) in cash, cash equivalents and restricted cash

 

46,971

 

 

 

(1,989

)

Cash, cash equivalents and restricted cash at beginning of period

 

32,310

 

 

 

40,100

 

Cash, cash equivalents and restricted cash at end of period

$

79,281

 

 

$

38,111

 

Supplemental disclosure of cash flow information

 

 

 

 

 

 

 

Cash paid during the period for interest

$

4,296

 

 

$

3,412

 

Non-cash investing and financing activities:

 

 

 

 

 

 

 

Purchases of property and equipment, not yet paid

$

411

 

 

$

408

 

 

See accompanying notes.


9


 

Dynavax Technologies Corporation

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

1. Organization and Summary of Significant Accounting Policies

Dynavax Technologies Corporation (“we,” “our,” “us,” “Dynavax” or the “Company”), is a commercial stage biopharmaceutical company focused on developing and commercializing novel vaccines. Our first marketed product, HEPLISAV-B® (Hepatitis B Vaccine (Recombinant), Adjuvanted) is approved in the United States and European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. We also manufacture and sell CpG 1018, the adjuvant used in HEPLISAV-B. We are working to develop CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.

Basis of Presentation

Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. In our opinion, these unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which we consider necessary to present fairly our financial position and the results of our operations and cash flows. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP have been condensed or omitted. Interim-period results are not necessarily indicative of results of operations or cash flows to be expected for a full-year period or any other interim-period. The condensed consolidated balance sheet at December 31, 2020 has been derived from audited financial statements at that date, but excludes disclosures required by GAAP for complete financial statements.

The unaudited condensed consolidated financial statements and these notes should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission (the “SEC”).

The unaudited condensed consolidated financial statements include the accounts of Dynavax and our wholly-owned subsidiaries, Dynavax GmbH located in Düsseldorf, Germany and Dynavax India LLP in India. All significant intercompany accounts and transactions among these entities have been eliminated from the condensed consolidated financial statements. We operate in one business segment: discovery, development and commercialization of novel vaccines.

Liquidity and Financial Condition

As of March 31, 2021, we had cash, cash equivalents and marketable securities of $232.7 million. As of March 31, 2021, the principal amount of our term loan was $180.9 million, including paid-in-kind interest. The term loan has a maturity date of December 31, 2023, unless earlier prepaid.

Prior to January 1, 2021, we incurred net losses in each year since our inception. For the three months ended March 31, 2021, we recorded net income of $0.9 million. We incurred net loss of $12.6 million for three months ended March 31, 2020. We cannot be certain that sales of our products, and the revenue from our other activities are sustainable. Further, we expect to continue to incur substantial expenses as we continue to invest in commercialization of HEPLISAV-B, development of our CpG 1018 adjuvant and clinical trials and other development. If we cannot generate a sufficient amount of revenue from product sales, we will need to finance our operations through strategic alliance and licensing arrangements and/or future public or private debt and equity financings. Raising additional funds through the issuance of equity or debt securities could result in dilution to our existing stockholders, increased fixed payment obligations, or both. In addition, these securities may have rights senior to those of our common stock and could include covenants that would restrict our operations.

We currently anticipate that our cash, cash equivalents and short-term marketable securities as of March 31, 2021, and anticipated revenues from HEPLISAV-B and CpG 1018 will be sufficient to fund our operations for at least the next 12 months from the date of this filing.

Our ability to raise additional capital in the equity and debt markets, should we choose to do so, is dependent on a number of factors, including, but not limited to, the market demand for our common stock, which itself is subject to a number of development and business risks and uncertainties, our creditworthiness and the uncertainty that we would be able to raise such additional capital at a price or on terms that are favorable to us. In addition, global financial crises and economic downturns, including those cause by widespread public health crises such as the COVID-19 pandemic, may cause extreme volatility and disruptions in capital and credit markets, and may impact our ability to raise additional capital when needed on acceptable terms, if at all. Adequate financing may not be available to us on acceptable terms, or at all.

10


Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Management’s estimates are based on historical information available as of the date of the condensed consolidated financial statements and various other assumptions we believe are reasonable under the circumstances. However, the worldwide spread of COVID-19 has resulted in a global slowdown of economic activity which is likely to decrease demand for a broad variety of goods and services, while also disrupting sales channels and marketing activities for an unknown period of time until the disease is contained. We are unable to predict the future effect resulting from the COVID-19 pandemic. Actual results could differ materially from management’s estimates.

Summary of Significant Accounting Policies

Revenue Recognition

We recognize revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of Accounting Standards Codification (“ASC”) 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Product Revenue, Net – HEPLISAV-B

We sell HEPLISAV-B to a limited number of wholesalers and specialty distributors in the U.S. (collectively, our “Customers”).

Revenues from product sales are recognized when we have satisfied our performance obligation, which is the transfer of control of our product upon delivery to the Customer. The timing between the recognition of revenue for product sales and the receipt of payment is not significant. Because our standard credit terms are short-term and we expect to receive payment in less than one year, there is no significant financing component on the related receivables. Taxes collected from Customers relating to product sales and remitted to governmental authorities are excluded from revenues.

Overall, product revenue, net, reflects our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If our estimates differ significantly from actuals, we will record adjustments that would affect product revenue, net in the period of adjustment.

Reserves for Variable Consideration

Revenues from product sales are recorded at the net sales price, which includes estimates of variable consideration such as product returns, chargebacks, discounts, rebates and other fees that are offered within contracts between us and our Customers, healthcare providers, pharmacies and others relating to our product sales. We estimate variable consideration using either the most likely amount method or the expected value method, depending on the type of variable consideration and what method better predicts the amount of consideration we expect to receive. We take into consideration relevant factors such as industry data, current contractual terms, available information about Customers’ inventory, resale and chargeback data and forecasted customer buying and payment patterns, in estimating each variable consideration. The variable consideration is recorded at the time product sales is recognized, resulting in a reduction in product revenue and a reduction in accounts receivable (if the Customer offsets the amount against its accounts receivable) or as an accrued liability (if we pay the amount through our accounts payable process). Variable consideration requires significant estimates, judgment and information obtained from external sources. The amount of variable consideration is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If our estimates differ significantly from actuals, we will record adjustments that would affect product revenue, net in the period of adjustment. If we were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of revenue that we report in a particular period. There have been no material adjustments to these estimates for the three months ended March 31, 2021 and 2020.

11


Product Returns: Consistent with industry practice, we offer our Customers a limited right of return based on the product’s expiration date for product that has been purchased from us. We estimate the amount of our product sales that may be returned by our Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We consider several factors in the estimation of potential product returns including expiration dates of the product shipped, the limited product return rights, available information about Customers’ inventory, shelf life of the product and other relevant factors.

Chargebacks: Our Customers subsequently resell our product to healthcare providers, pharmacies and others. In addition to distribution agreements with Customers, we enter into arrangements with qualified healthcare providers that provide for chargebacks and discounts with respect to the purchase of our product. Chargebacks represent the estimated obligations resulting from contractual commitments to sell product to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. Chargeback amounts are determined at the time of resale to the qualified healthcare providers by Customers, and we issue credits for such amounts generally within a few weeks of the Customer’s notification to us of the resale. Reserves for chargebacks consists of credits that we expect to issue for units that remain in the distribution channel inventories at each reporting period end that we expect will be sold to the qualified healthcare providers, and chargebacks for units that our Customers have sold to the qualified healthcare providers, but for which credits have not been issued.

Trade Discounts and Allowances: We provide our Customers with discounts which include early payment incentives that are explicitly stated in our contracts, and are recorded as a reduction of revenue in the period the related product revenue is recognized.

Distribution Fees: Distribution fees include fees paid to certain Customers for sales order management, data and distribution services. Distribution fees are recorded as a reduction of revenue in the period the related product revenue is recognized.

Rebates: Under certain contracts, customers may obtain rebates for purchasing minimum volumes of our product. We estimate these rebates based upon the expected purchases and the contractual rebate rate and record this estimate as a reduction in revenue in the period the related revenue is recognized.

Product Revenue, Net – CpG 1018

We also sell our CpG 1018 adjuvant to our collaboration partners for use in their development and/or commercialization of COVID-19 vaccine. We have determined that our collaboration partners meet the definition of customers under ASC 606. Therefore, we accounted for our CpG 1018 sales under ASC 606. Revenues from product sales are recognized when we have satisfied our performance obligation, which is the transfer of control of our product to the customer.

Overall, product revenue, net, reflects our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If our estimates differ significantly from actuals, we will record adjustments that would affect product revenue, net in the period of adjustment.  

Collaboration and Manufacturing Service Revenue

We have entered into collaborative arrangements and arrangements to provide manufacturing services to other companies. Such arrangements may include promises to customers which, if capable of being distinct, are accounted for as separate performance obligations. For agreements with multiple performance obligations, we allocate estimated revenue to each performance obligation at contract inception based on the estimated transaction price of each performance obligation. Revenue allocated to each performance obligation is then recognized when we satisfy the performance obligation by transferring control of the promised good or service to the customer. Collaboration and manufacturing service revenue are recorded in other revenue in the condensed consolidated statements of operations.

Inventories

Inventory is stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. We primarily use actual costs to determine our cost basis for inventories. Our assessment of market value requires the use of estimates regarding the net realizable value of our inventory balances, including an assessment of excess or obsolete inventory. We determine excess or obsolete inventory based on multiple factors, including an estimate of the future demand for our products, product expiration dates and current sales levels. Our assumptions of future demand for our products are inherently uncertain and if we were to change any of these judgments or estimates, it could cause a material increase or decrease in the amount of inventory reserves that we report in a particular period. For the three months ended March 31, 2021 and 2020, there were no inventory reserves recognized.

12


We consider regulatory approval of product candidates to be uncertain and product manufactured prior to the required regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory but are expensed as research and development costs. We begin capitalization of these inventory related costs once regulatory approval is obtained.

HEPLISAV-B was approved by the United States Food and Drug Administration (“FDA”) on November 9, 2017, at which time we began to capitalize inventory costs associated with the vial presentation of HEPLISAV-B. In March 2018, we received regulatory approval of the pre-filled syringe (“PFS”) presentation of HEPLISAV-B. Prior to FDA approval of HEPLISAV-B, all costs related to the manufacturing of HEPLISAV-B that could potentially be available to support the commercial launch of our products, were charged to research and development expense in the period incurred as there was no alternative future use. Prior to regulatory approval of PFS, costs associated with resuming operating activities at the Düsseldorf manufacturing facility were also included in research and development expense. Subsequent to regulatory approval of PFS, costs associated with resuming manufacturing activities at the Düsseldorf facility were included in cost of sales – product, until commercial production resumed in mid-2018 at which time these costs were recorded as raw materials inventory.

Recent Accounting Pronouncements

Accounting Standards Update 2019-12

In December 2019, the FASB issued Accounting Standards Update (“ASU”) No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). This ASU simplifies the accounting for income taxes by removing certain exceptions and improving consistent application in certain areas of Topic 740. The ASU is effective for annual periods beginning after December 15, 2020 with early adoption permitted. We adopted this ASU on January 1, 2021 and the adoption of this standard did not have a material impact on our consolidated financial statements.

Accounting Standards Update 2020-06

We adopted ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity on January 1, 2021 using the modified retrospective method. This ASU simplifies the accounting for convertible instruments and requires entities to use the if-converted method for all convertible instruments in calculating diluted earnings-per-share. Entities also need to recombine instruments that were previously separated into two units of account if separation is no longer required. The adoption of this ASU did not have a material impact on our condensed consolidated financial statements as there were no outstanding financial instruments that require recombination at January 1, 2021.  

Accounting Standards Update 2016-13

In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments. The standard changes the methodology for measuring credit losses on financial instruments and the timing of when such losses are recorded. For public business entities, excluding smaller reporting companies, this ASU is effective for fiscal years beginning after December 15, 2019. Furthermore, the one-time determination of whether an entity is eligible to be a smaller reporting company shall be based on an entity’s most recent determination as of November 15, 2019, in accordance with SEC regulations. Because we were a smaller reporting company based on the most recent determination as of November 15, 2019, this ASU and its subsequent updates, will be effective for fiscal years beginning after December 15, 2022. We are currently evaluating the impact this standard will have on our consolidated financial statements.

 

2. Fair Value Measurements

We measure fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

 

Level 1—Observable inputs, such as quoted prices in active markets for identical assets or liabilities;

 

Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and

13


 

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions.

Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. We review the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. There were no transfers between Level 1, 2 and 3 during the three months ended March 31, 2021.

The carrying amounts of cash equivalents, accounts and other receivables, accounts payable and accrued liabilities are considered reasonable estimates of their respective fair value because of their short-term nature.

Recurring Fair Value Measurements

The following table represents the fair value hierarchy for our financial assets (cash equivalents and marketable securities) and liabilities measured at fair value on a recurring basis (in thousands):

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

March 31, 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Assets